secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clene Inc. (CLNN)
CIK:        0001822791
Form:       8-K
Filed at:   2024-07-11T23:59:59+00:00
Accession:  0001437749-24-022529
Event type: regulatory
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clene to submit FDA briefing book for CNM-Au8 accelerated approval in ALS by July 13
--------------------------------------------------------------------------------

- Briefing book submission due July 13, 2024, for Type C interaction with FDA in Q3 2024.
- New post-hoc analyses include NfL biomarker reduction, survival data, and mechanism-of-action evidence.
- Data designed to address prior FDA comments from December 2023 meeting on accelerated approval path.
- Clene plans to disclose topline FDA feedback after the Type C interaction concludes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822791/000143774924022529/0001437749-24-022529-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822791/000143774924022529/clnn20240711_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-022529

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer